UBI集團訊息
United BioPharma Closes A Fundraising of NT$ 500 Million
UBP is a rapidly growing biopharmaceutical company Which reached numerous major milestones during the past year. These include completion of the clinical phase II trial of UB-421, completion of the 2000L process development program of UB-421 via Industrial Corporation Program funded by Industrial Development Bureau (IDB), Ministry of Economic Affairs (MOEA), completion of enrollment and test drug administration of UB-621 phase I clinical trial, completion of the process development of UB-221, an innovative anti-IgE mAb and biosimilar version of Humira® and Avastin®. In addition, construction of 2000L x 2 protein drug plant is to be completed ready for operations in the first quarter of 2017.
This financing will not only allow UBP to efficiently advance operations, research and clinical trials programs, but also reflects support from committed investors and new strategic investors for global business development.
About UBP (6471)
UBP was established in October 2013 as a monoclonal antibody business spinoff from United Biomedical, Inc., Asia, and is strategically partnering with Formosa Plastics Group. UBP has an integrated monoclonal antibody drug developing platform, and focuses on development, manufacturing, and marketing of innovative monoclonal antibody drugs and biosimilars. With a spirit of “innovation and practicality,” UBP is dedicated to addressing unmet medical needs to improve the health of mankind and economic advancement of Taiwan.
United BioPharma Forward-Looking Statements
The information in this press release should be considered accurate only as of the date of the release. UBP has no intention of updating and specifically disclaims any duty to update the information in this press release. The press release may contain forward-looking statements involving risks and uncertainties and UBP’s actual results may differ materially from those in the forward-looking statements.